Intranasal insulin (INI) has been shown to modulate food intake and food related activity in the central nervous system in humans. As INI increases cerebrospinal fluid insulin concentration, these effects have been postulated to be mediated via insulin action in the brain, although peripheral effects of insulin cannot be excluded. INI has been shown to lower plasma glucose in some studies but it is not known whether it regulates endogenous glucose production (EGP). 
Introduction
Dysregulation of insulin mediated suppression of hepatic glucose production (HGP) is a hallmark of type 2 diabetes (1). It is well established that activation of hepatic insulin receptors with ensuing activation of downstream insulin signaling pathways lowers hepatic glucose output by decreasing gluconeogenesis and increasing glycogen synthesis (1) . In addition to the direct action of insulin on hepatocytes, insulin can indirectly affect hepatic glucose production by altering free fatty acid (FFA) flux and suppression of glucagon secretion (2) (3) (4) . Animal have indicated that insulin may also indirectly regulate hepatic glucose output via effects on the central nervous system (CNS); the so called 'brain-liver axis' (1; 5; 6).
Injection of insulin into the 3 rd cerebral ventricle in mice activates K ATP channels in the mediobasal hypothalamus (via activation of the insulin receptor-PI3 kinase pathway), which activates second order neurons in the brainstem. This in turn lowers expression of gluconeogenic enzymes and glucose production by the liver an effect that is abrogated with surgical resection of the hepatic branch of the vagus nerve (6) . More recently CNS insulin action in the dorsal vagal complex has also been shown to regulate HGP via activation of the insulin-insulin receptor-ERK kinase pathway (7) . These brain-liver axis effects are seen in the absence of changes in plasma insulin concentration (5) (6) (7) . A brain-liver axis has also been demonstrated in dogs. Insulin delivery into the head arteries augments hepatic glycogen synthesis and reduces mRNA expression of gluconeogenic enzymes but with no acute change in HGP (8) .
In recent human studies a single dose of intranasal insulin (INI), at a dose of 160 IU, has been shown to modulate food-related activity in the CNS (9) , reduce overall food intake in males (10), improve cognitive performance in females (10) and reduce intake of palatable food and increase satiety in females (11) . These effects are likely mediated by direct CNS insulin action, although other non-CNS effects of nasally administered insulin cannot be definitively excluded. INI, at a lower dose of 40IU, has previously been shown to increase CSF insulin concentration with no significant change in measured serum insulin concentration sampled at 10 minute intervals for the 1 st 40 minutes and 20 minute intervals for a further 40 minutes (12) . Small lipophilic peptides such as insulin can potentially enter the CNS directly by diffusing across the olfactory epithelia and intercellular spaces into the subarachnoid space (12; 13) . Intranasally administered peptides can also enter the CNS indirectly via uptake into the olfactory bulb and axonal transport (12; 13) . Recent studies in humans have also shown that INI, administered at a higher dose of 160IU, can acutely lower plasma glucose and alter peripheral insulin sensitivity (11; 14; 15) , an effect postulated to occur via insulin delivery to the CNS. However, the higher dose (160IU) of INI transiently increased peripheral insulin concentration (9; 14; 15) which may contribute to the acute effects of INI on peripheral glucose metabolism and insulin sensitivity (11; 14; 15) .
In the present single blind, placebo controlled, crossover study, we aimed to investigate during one visit and placebo during the other. The order of the visits was randomized.
Insulin dosing:
Pilot studies indicated that peripheral insulin spillover was inevitable, with doses ranging from 80 IU to as low as 10 IU (Supplementary Figure S1 ). 40 IU of INI was chosen as this dose has previously been shown to increase CSF insulin concentration in humans (12) and in our pilot studies a higher dose of INI (80 IU) resulted in a greater spillover of insulin lispro into the peripheral circulation (Supplementary Figure S1) . In order to ensure similar venous plasma insulin concentrations between treatments, 0.005 IU/kg insulin lispro was infused intravenously over 30 min, starting at the time of administration of INP. The intravenous insulin lispro dose was identified in a pilot study with varied doses (data not shown).
Study outline (Figure 1)
Participants were admitted to the Metabolic Test Centre of Toronto General Hospital the morning before the study. Volunteers had a standardized mixed meal at 5pm and were not permitted any food or drink orally except water until the conclusion of the study. The following day at 7am (t=-120 minutes), an arterial pancreatic clamp was started and continued for the remainder of the study (until 3pm, t=360 minutes) to neutralize any thereafter till the conclusion of the study (t=30 minutes to 360 minutes). 20% dextrose solution was administered to maintain euglycemia as necessary.
Laboratory Methods
Plasma was separated from blood samples in a refrigerated centrifuge at 3000 rpm for 15 min at 4º C. Sodium azide (70 mg/l blood) (Sigma Aldrich, Oakville, Canada) and aprotinin (1.94 mg/l blood) (Sigma Aldrich, Oakville, Canada) were added to the plasma to prevent hydrolysis and protein degradation. Plasma was dried, derivatized and stable isotope enrichments determined (16) . Derivatized samples were analyzed with GC/MS (Agilent 5975/6890N, Agilent Technologies Canada Inc, Mississauga, ON, Canada) with electron impact ionization using helium as the carrier gas. Selective ion monitoring at m/z =242 and 244 was performed. Atom percent excess fraction (APE) was calculated for each sample as APE= tracer/(tracer + tracee).
Commercial kits were used to measure total insulin (Millipore, Billerica, MA, USA), growth hormone (Abcam Inc, Toronto, Canada), FFA (Wako Industrials, Osaka, Japan), TG (Roche Diagnostics) and glucagon (Millipore). An insulin lispro (Millipore) kit (specificity for lispro:
100%, specificity for human insulin ~0.05%) was used to measure lispro concentration in our pilot studies (Supplementary figure S1).
Analysis of endogenous glucose production
EGP was calculated as described previously (17) . During steady state, rate of glucose appearance (R a ) = rate of glucose disappearance (R d ) where R a = tracer infusion rate /APE fraction. Endogenous glucose production (EGP) rate = R a -glucose infusion rate (17) .
Statistics
Results are presented as mean ± SEM. Paired t-test was used to compare plasma glucose, venous insulin, plasma glucagon, glucose infusion rates and endogenous glucose production. A p value < 0.05 was considered significant. Post hoc analysis revealed a power of 98% to detect a change in EGP as well as plasma insulin in the final 180 minutes of the study (t=180-360). The power to detect a change in insulin concentration during the entire study was 94%.
Study oversight
The study was carried out according to the principles of the Declaration of Helsinki and was approved by University Health Network Research Ethics Board, Toronto. All participants gave written informed consent.
Results

Plasma glucose and insulin concentrations. Mean glucose concentration over time during
the study is depicted in Figure 2A . 
INI treatment increases intravenous glucose infusion requirements to maintain euglycemia.
Intravenous glucose in the form of 20% dextrose was infused, as required, to maintain euglycemia. The mean dextrose infusion rate over time is illustrated in Figure 2C 40 IU of INI has previously been shown to rapidly raise CSF insulin concentration (12) without increasing serum insulin. In our hands, under conditions of an arterial pancreatic clamp during which endogenous insulin secretion cannot be modulated, 40 IU of INI (insulin lispro, Eli Lilly, Canada) also transiently raised venous insulin concentration as measured by a specific lispro assay. We also detected peripheral spillover with a dose as low as 10 IU (Supplementary Figure S1) . In this study, we administered the lowest dose of nasal insulin that has previously been shown to raise CSF insulin concentration (12) (11; 14) as well as improved peripheral insulin sensitivity (15) . These studies did not measure plasma insulin as frequently as in the current study. In one study (14) , plasma insulin (measured every 30 minutes) was significantly higher at 30 minutes with a decline in C-peptide and subsequent insulin concentration, suggestive of peripheral spill over of insulin with decline in endogenous insulin secretion. Plasma insulin concentration (measured every 15 minutes) was transiently higher at 15 minutes in a recent study by the same group after administration of 160 IU of INI (15) . Insulin concentration was not reported for the first 45 minutes in the study by Hallschmid et al (11) . In these studies of INI, (19) .
Although the exact mechanism by which INI lowers EGP remains to be determined, reduced expression of hepatic gluconeogenic enzymes such as PEPCK and G6Pase via hepatic vagal efferents secondary to CNS insulin action, is a plausible explanation. This is based on the previous findings that 1) INI increases CSF insulin concentration (12) and 2) that in rodents intracerebroventricular insulin injection reduces expression of gluconeogenic enzymes and hepatic glucose production, an effect abrogated by resection of hepatic vagal efferents (5; 6). A previous study has demonstrated a reduction in FFA with 160IU of INI treatment in humans with no reported change in plasma insulin concentration (18) , although as discussed above at this dose peripheral insulin spillover may have contributed. In the current study, mean FFA between 180 and 360 minutes tended to be lower with INI, but did not reach statistical significance. In view of the relatively small sample size of the current study we cannot exclude a significant difference in FFA had we studied more individuals, and therefore reduced FFA flux to the liver could potentially contribute to the lowering of hepatic glucose production. There were no significant differences in the concentration of growth hormone and glucagon between treatments. Previous studies in dogs have demonstrated that pulmonary insulin delivery can regulate insulin sensitivity independent of plasma insulin concentration (20) . Nasally inhaled aerosols have been shown to be deposited in the lungs (21) . INI can potentially deliver insulin to the lungs with secondary effects on glucose metabolism. It is not possible to rule out as yet unidentified CNS and/or non-CNS mediated effects as contributors to EGP reduction.
Although the present study suggests that INI possibly acting via the CNS, can regulate EGP, the contribution of this pathway to glucose homeostasis in normal human physiology remains to be determined. Under our arterial pancreatic clamp conditions, the pancreas is unable to modulate endogenous insulin and glucagon secretion with changing glucose concentration. Additionally with an arterial pancreatic clamp, as was the case with previous rodent studies (5; 6), portal and peripheral insulin concentrations are likely to be identical, since the normal portal-peripheral insulin concentration gradient is abolished when insulin delivery does not occur via the portal circulation. In normal physiology, portal insulin concentration is ~3 times greater than its peripheral concentration (8; 22) . Hence, during an arterial pancreatic clamp there is relative hepatic insulin deficiency (8; 22) . Under these conditions, CNS-mediated effects of insulin are dominant and lower EGP. However with an arterial pancreatic clamp, the portal to peripheral glucagon gradient (23) is also lost which may have minimized the effects of relative hepatic insulin deficiency on EGP. Consistent with the hypothesis that only under conditions of relative hepatic insulin deficiency can CNS insulin lower EGP, in experiments carried out in dogs, when a pancreatic clamp is instituted with normal portal-peripheral insulin concentration gradient, CNS insulin delivery augments glycogen synthesis but has no effect on EGP four hours after administration (8) . However, in this study, the CNS to non-CNS insulin gradient was not maintained. Resistance to direct insulin action in the liver and increased hepatic glucose production is a hallmark of type 2 diabetes (1). Current treatment modalities for type 2 diabetes have potential side effects, including weight gain with subcutaneous insulin and sulphonylureas which can potentially exacerbate hepatic insulin resistance (26) . It remains to be determined whether INI can acutely lower EGP in individuals with insulin resistance and type 2 diabetes and whether chronic treatment with INI affects glycemic control. An additional potential advantage of INI is that unlike subcutaneous insulin, it is less likely to cause weight gain. Animal studies have suggested that CNS insulin action reduces appetite and results in weight loss (27) . In human studies with INI, an acute reduction in appetite has been reported after a single dose in men (10) with a reduction in postprandial satiety and intake of palatable food in women (11) . Additionally, 8 weeks of INI treatment in slim healthy volunteers, modestly reduced fat mass and body weight in men with modest weight gain seen in women which is thought to be due to a rise in extracellular water but importantly with no change in body fat (19) . It must be noted however that in rodent models of insulin resistance induced by a high fat diet, CNS-mediated effects of insulin are blunted (28) , suggestive of the presence of hypothalamic insulin resistance. It remains to be determined whether a similar phenomenon occurs in obese insulin resistant humans.
In conclusion, we have shown that INI, at a dose that is known to increase CSF insulin concentration, lowers EGP under conditions of experimental portal hypoinsulinemia compared to INP. This effect is seen despite similar venous insulin concentration between treatments. Additional studies are needed to evaluate whether this pathway is amenable to therapeutic manipulation in insulin resistance and type 2 diabetes.
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